Could standard cancer treatment work for frailer patients?
NCT ID NCT04253964
Summary
This study is testing if a standard first-line chemo/immunotherapy treatment for advanced lung cancer works as well and is as safe for patients in poorer health (Performance Status 2) as it is for patients in better health (Performance Status 0-1). It will enroll about 105 adults with untreated, advanced non-small cell lung cancer. The main goal is to see if the treatment keeps the cancer from worsening for a similar length of time in both groups, while also checking side effects and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONSMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27105, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.